Wockhardt Share Price Today (WOCKPHARMA)
TODAY IN ONE LINE
WOCKPHARMA fell 1.4% on light volume, in line with Nifty's -0.9% move, supported by recent strong earnings.
With a market cap of ₹30,350.29 Cr., it trades at a P/E of 144.46. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Wockhardt flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 29.9% and Profit up 688.0%
- ●Healthy Operating MarginsOPM is structurally strong at 19.3%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 6.1%
- ●Expensive ValuationTrading at a high P/E ratio of 150.3x
- ●Rising Receivables vs SalesReceivables grew 20.1% outpacing sales growth of 7.6%
Latest Wockhardt News
What changed recently?
Recent events, corporate actions, and announcements.
Wockhardt Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Wockhardt Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Wockhardt Ltd trades at a P/E of 144.46× and P/B of 6.23×, against the Healthcare sector median P/E of 40.48×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Wockhardt Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Wockhardt Ltd — derived from the live tape, not yesterday's close.
Wockhardt Ltd last traded at ₹1,869.4 with an intraday range of ₹1,827.1–₹1,890 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1869.40| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2023.03 | +153.63 | +8.22% |
| R3 | 1960.13 | +90.73 | +4.85% |
| R2 | 1925.07 | +55.67 | +2.98% |
| R1 | 1897.23 | +27.83 | +1.49% |
| PIVOT | 1862.17 | -7.23 | -0.39% |
| CURRENT | 1869.40 | — | — |
| S1 | 1834.33 | -35.07 | -1.88% |
| S2 | 1799.27 | -70.13 | -3.75% |
| S3 | 1771.43 | -97.97 | -5.24% |
| S4 | 1708.53 | -160.87 | -8.61% |
WOCKPHARMA is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹1855–₹1890
Trading Below opening range, showing Bearishness
Wockhardt Ltd financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Wockhardt Ltd — consolidated or standalone — with margins, YoY growth and key ratios inline.
Wockhardt Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹30,350.29 Cr. and reported EPS of ₹13.10.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 3,012 | 3,373 ▲ 12.0% |
| Sales Growth YoY %Derived | 7.65% | 11.99% |
| Other Income | 62 | 111 ▲ 79.0% |
| Total Income | 3,074 | 3,484 ▲ 13.3% |
| 1,132 | 1,132 ▲ 0.0% | |
| Gross ProfitDerived | 1,880 | 2,241 ▲ 19.2% |
| Gross Margin %Derived | 62.42% | 66.44% |
| 1,487 | 1,589 ▲ 6.9% | |
| EBITDA (Operating Profit)Derived | 393 | 652 ▲ 65.9% |
| OPM %Derived | 13.05% | 19.33% |
| 471 | 355 ▼ 24.6% | |
| Profit Before Tax (PBT) | -16 | 238 ▲ 1587.5% |
| 41 | 39 ▼ 4.9% | |
| Effective Tax %Derived | -256.25% | 16.39% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | -57 | 199 ▲ 449.1% |
| Less: Non-controlling Interests | -10 | -14 ▼ 40.0% |
| Net Profit (Owner's PAT)Derived | -47 | 213 ▲ 553.2% |
| Net Profit Margin %Derived | -1.56% | 6.31% |
| PAT Growth YoY %Derived | 89.85% | 553.19% |
| Earnings Per Share (EPS ₹) | -2.89 | 13.11 ▲ 553.6% |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 71 | 419 ▲ 490.1% |
| Total Expenses (incl. D&A & Interest) | 3,090 | 3,246 ▲ 5.0% |
| Material Cost % of RevenueDerived | 20.32% | 19.98% |
| Employee Cost % of RevenueDerived | 21.61% | 21.49% |
| Other Cost % of RevenueDerived | 27.76% | 25.62% |
| Interest Coverage (x)Derived | 0.69x | 2.00x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3,937 | 4,158 ▲ 5.6% | 2,844 ▼ 31.6% | 2,708 ▼ 4.8% | 3,230 ▲ 19.3% | 2,651 ▼ 17.9% | 2,798 ▲ 5.5% | 3,012 ▲ 7.6% | 3,373 ▲ 12.0% | |
| Sales Growth YoY %Derived | — | 5.63% | -31.61% | -4.77% | 19.26% | -17.93% | 5.55% | 7.65% | 11.99% | |
| Other Income | 120 | 21 ▼ 82.5% | 39 ▲ 84.6% | 132 ▲ 240.8% | 20 ▼ 84.9% | 122 ▲ 510.0% | 83 ▼ 32.0% | 62 ▼ 25.3% | 111 ▲ 79.0% | |
| Total Income | 4,057 | 4,179 ▲ 3.0% | 2,883 ▼ 31.0% | 2,841 ▼ 1.5% | 3,250 ▲ 14.4% | 2,773 ▼ 14.7% | 2,881 ▲ 3.9% | 3,074 ▲ 6.7% | 3,484 ▲ 13.3% | |
1,798 | 1,815 ▲ 1.0% | 1,203 ▼ 33.7% | 1,135 ▼ 5.6% | 1,267 ▲ 11.6% | 1,111 ▼ 12.3% | 1,165 ▲ 4.9% | 1,132 ▼ 2.8% | 1,132 ▲ 0.0% | ||
| Gross ProfitDerived | 2,139 | 2,344 ▲ 9.6% | 1,641 ▼ 30.0% | 1,573 ▼ 4.1% | 1,963 ▲ 24.8% | 1,540 ▼ 21.5% | 1,633 ▲ 6.0% | 1,880 ▲ 15.1% | 2,241 ▲ 19.2% | |
| Gross Margin %Derived | 54.34% | 56.36% | 57.68% | 58.07% | 60.77% | 58.09% | 58.36% | 62.42% | 66.44% | |
2,138 | 2,234 ▲ 4.5% | 1,522 ▼ 31.9% | 1,636 ▲ 7.5% | 1,665 ▲ 1.8% | 1,439 ▼ 13.6% | 1,594 ▲ 10.8% | 1,487 ▼ 6.7% | 1,589 ▲ 6.9% | ||
| EBITDA (Operating Profit)Derived | 2 | 110 ▲ 5888.5% | 119 ▲ 8.6% | -63 ▼ 153.0% | 298 ▲ 572.8% | 101 ▼ 66.1% | 39 ▼ 61.4% | 393 ▲ 907.7% | 652 ▲ 65.9% | |
| OPM %Derived | 0.05% | 2.64% | 4.19% | -2.33% | 9.23% | 3.81% | 1.39% | 13.05% | 19.33% | |
47 | 431 ▲ 820.2% | 500 ▲ 16.0% | 353 ▼ 29.5% | 363 ▲ 2.9% | 259 ▼ 28.7% | 514 ▲ 98.5% | 471 ▼ 8.4% | 355 ▼ 24.6% | ||
| Profit Before Tax (PBT) | -641 | -300 ▲ 53.2% | -342 ▼ 13.9% | -568 ▼ 66.2% | -411 ▲ 27.7% | -624 ▼ 51.8% | -420 ▲ 32.7% | -16 ▲ 96.2% | 238 ▲ 1587.5% | |
26 | -84 ▼ 425.5% | -204 ▼ 144.0% | -272 ▼ 33.1% | -132 ▲ 51.4% | -3 ▲ 97.7% | 52 ▲ 1833.3% | 41 ▼ 21.2% | 39 ▼ 4.9% | ||
| Effective Tax %Derived | -4.01% | 27.86% | 59.67% | 47.79% | 32.12% | 0.48% | -12.38% | -256.25% | 16.39% | |
| Profit/Loss from Discontinued Ops | — | — | 95 | 985 ▲ 942.0% | — ▼ 100.0% | — | — | — | — | |
| Total Profit for Period | -667 | -217 ▲ 67.5% | -43 ▲ 80.0% | 689 ▲ 1687.0% | -279 ▼ 140.5% | -621 ▼ 122.6% | -472 ▲ 24.0% | -57 ▲ 87.9% | 199 ▲ 449.1% | |
| Less: Non-controlling Interests | -59 | -22 ▲ 62.2% | 26 ▲ 216.7% | 3 ▼ 90.2% | -35 ▼ 1478.0% | -62 ▼ 77.1% | -9 ▲ 85.5% | -10 ▼ 11.1% | -14 ▼ 40.0% | |
| Net Profit (Owner's PAT)Derived | -608 | -195 ▲ 68.0% | -69 ▲ 64.4% | 686 ▲ 1091.1% | -244 ▼ 135.6% | -559 ▼ 129.1% | -463 ▲ 17.2% | -47 ▲ 89.8% | 213 ▲ 553.2% | |
| Net Profit Margin %Derived | -15.45% | -4.68% | -2.43% | 25.33% | -7.55% | -21.09% | -16.55% | -1.56% | 6.31% | |
| PAT Growth YoY %Derived | — | 68.02% | 64.42% | 1,091.13% | -135.57% | -129.10% | 17.17% | 89.85% | 553.19% | |
| Earnings Per Share (EPS ₹) | -42.30 | -13.52 ▲ 68.0% | -4.81 ▲ 64.4% | 47.64 ▲ 1090.4% | -16.94 ▼ 135.6% | -38.80 ▼ 129.0% | -30.18 ▲ 22.2% | -2.89 ▲ 90.4% | 13.11 ▲ 553.6% | |
| Diluted Shares Outstanding (Cr) | 14 | 14 ▲ 0.1% | 14 ▲ 0.0% | 14 ▲ 0.0% | 14 ▲ 0.0% | 14 ▲ 0.0% | 15 ▲ 6.5% | 16 ▲ 5.9% | 16 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 139 | 9 ▼ 93.5% | 101 ▲ 1020.8% | -4 ▼ 103.9% | -27 ▼ 578.4% | 78 ▲ 388.9% | 6 ▼ 92.3% | 71 ▲ 1083.3% | 419 ▲ 490.1% | |
| Total Expenses (incl. D&A & Interest) | 4,698 | 4,480 ▼ 4.7% | 3,225 ▼ 28.0% | 3,409 ▲ 5.7% | 3,661 ▲ 7.4% | 3,397 ▼ 7.2% | 3,301 ▼ 2.8% | 3,090 ▼ 6.4% | 3,246 ▲ 5.0% | |
| Material Cost % of RevenueDerived | 22.04% | 20.54% | 21.86% | 25.20% | 18.95% | 19.54% | 22.16% | 20.32% | 19.98% | |
| Employee Cost % of RevenueDerived | 23.80% | 22.53% | 26.14% | 28.17% | 23.19% | 24.03% | 22.48% | 21.61% | 21.49% | |
| Other Cost % of RevenueDerived | 30.49% | 31.20% | 27.36% | 32.23% | 28.36% | 30.25% | 34.49% | 27.76% | 25.62% | |
| Interest Coverage (x)Derived | -0.58x | -0.21x | -0.38x | -1.24x | 0.17x | -0.50x | -0.60x | 0.69x | 2.00x |
Wockhardt segment analysis : revenue and profit mix.
Disclosed business segments at Wockhardt with their share of revenue and profit, switchable between consolidated and standalone reporting.
Wockhardt discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Wockhardt Ltd.
Our AI distills the core fundamental drivers supporting Wockhardt Ltd, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Wockhardt Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Promoter holding 49.08% demonstrates strong insider confidence and governance commitment.
Quarterly sales grew 29.90% YoY, signaling recent revenue acceleration momentum.
Quarterly profit surged 688% YoY, indicating significant loss reduction trajectory.
TTM revenue growth 26% reflects strong short-term commercial traction.
Robust R&D pipeline with multiple phase-3 trials in infectious disease therapeutics.
Key Risks.
TTM net margin 3.30% far below peer median, indicating severe pricing pressure.
Debt-to-equity 0.4228 strains balance sheet; total debt ₹0.02 LCr.
Operating cash flow per share negative at -₹23.82, liquidity under pressure.
Zero dividend yield offers no direct shareholder returns or capital distribution.
P/E 154.09x and EV/EBITDA 56.90x severely overvalued versus sector peers.
Flip Conditions.
Valuation risk. a P/E above 188 (~4.6× the sector multiple of 40.5) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Wockhardt Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Wockhardt Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Wockhardt Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Wockhardt Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Wockhardt Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Wockhardt Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Wockhardt Ltd stood at 42.1% of traded volume, against a 20-day average of 39.1%.
Wockhardt announcements: results, concalls, ratings, M&A.
Filings Wockhardt sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Wockhardt files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 90 documents below.
Copy of Newspaper Publication
Pursuant to Regulation 30 read with Schedule III (Part A Para A) and other applicable regulations of SEBI (Listing Obligations and Disclosure…
Shareholders meeting
The 27th Annual General Meeting ( 27th AGM ) of the Members of Wockhardt Limited will be held on Monday, 10th August, 2026 at 3:30 p.m. (IST),…
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please findenclosed the Certificate received from MUFG Intime…
Copy of Newspaper Publication
Pursuant to Regulation 30 read with Schedule III (Part A Para A) of SEBI Listing Regulations, please find enclosed herewith newspaper extracts of…
Disclosure under SEBI Takeover Regulations
Wockhardt Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Wockhardt dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Wockhardt has declared, sequenced by announce and record date.
Wockhardt corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Wockhardt insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Wockhardt as reported to SEBI — buying and selling signals from the people who know the business best.
Wockhardt insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Muayyad Khorakiwala | Insider | 27 Dec 2024 | buy | +1.8 K | — | — |
About Wockhardt Ltd: business, sector, key facts.
What Wockhardt Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Wockhardt Ltd operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: WOCKPHARMA, BSE: 532300.
Wockhardt Limited is a multinational pharmaceutical and biotechnology company with a global presence, operating in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and other international markets. Their core business encompasses the manufacturing and trading of a wide range of pharmaceutical, medicinal, botanical, and chemical products.
A significant portion of Wockhardt's business focuses on the research and development of innovative products, particularly in the area of infectious diseases. They have several products in various stages of clinical trials, including WCK5222 (phase 3, for sepsis and pneumonia), WCK 4282 (phase 3, for ESBL infections), WCK 6777 (phase 1, for gram-negative infections), and WCK 4873 (phase 3, for community-acquired bacterial pneumonia). This commitment to research and development underscores their strategic focus on advanced therapeutics.
Beyond infectious disease treatments, Wockhardt also manufactures and commercializes a diverse portfolio of products including rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters, and novel products along with their associated delivery devices. This demonstrates a commitment to addressing a broad range of healthcare needs, extending beyond infectious diseases into metabolic disorders.
Wockhardt's product portfolio further includes established commercial products such as Biovac-B (hepatitis B vaccine), WEPOX (recombinant human erythropoietin), WOSULIN (recombinant human insulin), and GLARITUS (recombinant insulin glargine). These commercially available products contribute significantly to their revenue stream and establish a strong market presence.
In addition to its own product development and commercialization, Wockhardt offers contract manufacturing services and provides active pharmaceutical ingredients (APIs) to other companies. This diversification of revenue streams through contract manufacturing enhances the company's overall financial stability and resilience.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Wockhardt Ltd (WOCKPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Wockhardt Ltd (WOCKPHARMA)?
The current share price of Wockhardt Ltd (WOCKPHARMA) is ₹1,869.4. Today, the stock has declined by ₹26.90 (1.42%), trading in a range of ₹1,827.1 to ₹1,890. The stock opened at ₹1,890 with a trading volume of 6,94,474 shares.
02Is Wockhardt Ltd stock a good investment for long-term?
Wockhardt Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹30,350.29 crores, P/E ratio of 144.46, ROE of 6.11%, and ROCE of 7.55%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Wockhardt Ltd stock?
The 52-week high price of Wockhardt Ltd (WOCKPHARMA) is ₹2,422.3, while the 52-week low is ₹1,086.7. Currently trading at ₹1,869.4, the stock is 58.6% away from its 52-week low and 22.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Wockhardt Ltd stock at the current price?
Whether to buy Wockhardt Ltd stock at ₹1,869.4 depends on multiple factors. The stock is currently trading with a P/E ratio of 144.46 and P/B ratio of 6.23. Today's performance shows a loss of 1.42%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Wockhardt Ltd and when is the next dividend?
Wockhardt Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,869.4, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Wockhardt Ltd?
Wockhardt Ltd's key financial metrics include: P/E Ratio: 144.46, P/B Ratio: 6.23, ROE: 6.11%, ROCE: 7.55%, Dividend Yield: 0.00%, EPS: ₹13.10, Book Value: ₹304, and Debt-to-Equity: 0.45. The company's market cap stands at ₹30,350.29 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Wockhardt Ltd stock performing today in the market?
Wockhardt Ltd stock opened at ₹1,890 and is currently trading at ₹1,869.4, showing a decline of ₹26.90 (1.42%). The intraday high is ₹1,890 and low is ₹1,827.1. The trading volume stands at 6,94,474 shares, indicating moderate market participation today.
08What is the P/E ratio of Wockhardt Ltd and what does it indicate?
Wockhardt Ltd has a Price-to-Earnings (P/E) ratio of 144.46, which means investors are willing to pay ₹144.46 for every ₹1 of earnings. With an EPS of ₹13.10, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Wockhardt Ltd (WOCKPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.